Using genetic variants to evaluate the causal effect of cholesterol lowering on head and neck cancer risk: a Mendelian randomization study

Mark Gormley[1,2,3]*, James Yarmolinsky[1,3], Tom Dudding[1,2,3], Kimberley Burrows[1,3], Richard M Martin[1,3,4], Steven Thomas[2,4], Jessica Tyrrell[5], Paul Brennan[6], Miranda Pring[2], Stefania Boccia[7,8], Andrew F Olshan[9], Brenda Diergaarde[10], Rayjean J. Hung[11,12], Geoffrey Liu[12,13], Danny Legge[14], Eloiza H Tajara[15], Patricia Severino [16], Martin Lacko[17], Andrew R Ness[4], George Davey Smith[1,3], Emma E Vincent[1,3,14&], Rebecca C Richmond[1,3&]

[1] MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

[2] Bristol Dental Hospital and School, University of Bristol, Bristol, UK.

[3] Department of Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

[4] National Institute for Health Research Bristol Biomedical Research Centre at the University Hospitals Bristol and Weston NHS Foundation Trust, University of Bristol, Bristol, UK.

[5] University of Exeter Medical School, RILD Building, RD&E Hospital, Exeter, UK.

[6] Genetic Epidemiology Group, World Health Organization, International Agency for Research on Cancer, Lyon, France.

[7] Sezione di Igiene, Istituto di Sanità Pubblica, Università Cattolica del Sacro Cuore, Roma,

Italy.

[8] Department of Woman and Child Health and Public Health, Public Health Area, Fondazione

Policlinico Universitario A. Gemelli IRCCS, Roma, Italy.

[9] Department of Epidemiology, Gillings School of Global Public Health, University of North

Carolina, US.

[10] Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh,

and UPMC Hillman Cancer Center, Pittsburgh, US.

[11] Prosserman Centre for Population Health Research, Lunenfeld-Tanenbaum Research

Institute, Sinai Health System, Toronto, Canada.

[12] Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.

[13] Princess Margaret Cancer Centre, Toronto Canada.

[14] School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.

[15] School of Medicine of São José do Rio Preto, São Paulo, Brazil.

[16] Albert Einstein Research and Education Institute, Hospital Israelita Albert Einstein, São

Paulo, Brazil.

[17] Department of Otorhinolaryngology and Head and Neck Surgery, Research Institute GROW,

Maastricht University Medical Center, Maastricht, The Netherlands.

Corresponding author

* Email: mark.gormley@bristol.ac.uk

Author contributions

& These authors also contributed equally to this work.

E.E.V. and R.C.R. are joint senior authors. M.G., R.C.R. and E.E.V. conceived the study and M.G. carried out data curation and formal analysis. K.B. performed the GWAS of head and neck cancer in UK Biobank. Head and neck cancer summary genetic data was obtained through multiple collaborations from studies lead and curated by A.R.N., S.T., A.F.O., B.D., R.J.H., G.L., M.L., E.T., S.B. and P.B. Expert guidance on MR methodology was provided by R.C.R., J.Y., G.D.S. and R.M.M., R.C.R., G.D.S, J.T., S.T., P.B., R.M.M. and A.R.N. provided expertise on both observational and genetic epidemiological methodology and analysis. The initial manuscript was drafted by M.G., R.C.R. and E.E.V. All authors (M.G., J.Y., T.D., K.B., R.M.M., S.T., J.T., A.R.N., P.B., M.P., S.B., A.F.O., B.D, R.J.H., G.L., D.L., E.H.T., P.S., M.L., A.R.N., G.D.S., E.E.V. and R.C.R.) contributed to the interpretation of the results, editing and critical revision of the manuscript. M.G.'s PhD supervisory team includes R.C.R., E.E.V., J.T., A.R.N and G.D.S.

Abbreviations: HNSCC, head and neck squamous cell carcinoma; OC, oral cancer; OPC,

oropharyngeal cancer; HPV, human papilloma virus; MR, Mendelian randomization; GWAS,

genome-wide association study; SNP, single nucleotide polymorphism; PCA, principal

component analysis; NOME, no measurement error; SIMEX, simulation extrapolation; MR-

PRESSO, Mendelian Randomization Pleiotropy RESidual Sum and Outlier; GAME-ON, Genetic

Associations and Mechanisms in Oncology; HMGCR, 3-hydroxy-3-methylglutaryl-CoA

reductase; NPC1L1, NPC1 like intracellular cholesterol transporter 1; CETP, cholesteryl ester

transfer protein; PCSK9, proprotein convertase subtilisin/kexin type 9; LDLR, low-density

lipoprotein receptor; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density

lipoprotein cholesterol; LD, linkage disequilibrium; OR, odds ratio; se, standard error; IVW,

inverse variance weighted; CI, confidence intervals; P, *p*-value.

Abstract

Introduction

Head and neck squamous cell carcinoma (HNSCC), which includes cancers of the oral

cavity and oropharynx, is a cause of substantial global morbidity and mortality. Strategies to

reduce disease burden include discovery of novel therapies and repurposing of existing drugs.

Statins are commonly prescribed for lowering circulating cholesterol by inhibiting HMG-CoA

reductase (HMGCR). Results from some observational studies suggest that statin use may

reduce HNSCC risk. We appraised the relationship of genetically-proxied cholesterol-lowering

drug targets and other circulating lipid traits with oral (OC) and oropharyngeal (OPC) cancer

risk.

Methods and findings

We conducted two-sample Mendelian randomization (MR). For the primary analysis,

germline genetic variants in *HMGCR*, *NPC1L1*, *CETP, PCSK9* and *LDLR* were used to proxy the

effect of low-density lipoprotein cholesterol (LDL-C) lowering therapies. In secondary

analyses, variants were used to proxy circulating levels of other lipid traits in a genome-wide

association study (GWAS) meta-analysis of 188,578 individuals. Both primary and secondary

analyses aimed to estimate the downstream causal effect of cholesterol lowering therapies

on OC and OPC risk.

The second sample for MR was taken from a GWAS of 6,034 OC and OPC cases and

6,585 controls (GAME-ON). Analyses were replicated in UK Biobank, using 839 OC and OPC

cases and 372,016 controls and the results of the GAME-ON and UK Biobank analyses

combined in a fixed-effects meta-analysis.

We found limited evidence of a causal effect of genetically-proxied LDL-C lowering

using HMGCR, NPC1L1, CETP or other circulating lipid traits on either OC or OPC risk.

Genetically-proxied PCSK9 inhibition equivalent to a 1 mmol/L (38.7 mg/dL) reduction in LDL-

C was associated with an increased risk of OC and OPC combined (OR 1.8 95%CI 1.2, 2.8, p=

9.31 x10^{-05}), with good concordance between GAME-ON and UK Biobank (I^2= 22%). Effects

for PCSK9 appeared stronger in relation to OPC (OR 2.6 95%CI 1.4, 4.9) than OC (OR 1.4 95%CI

0.8, 2.4). LDLR variants, resulting in genetically-proxied reduction in LDL-C equivalent to a 1

mmol/L (38.7 mg/dL), reduced the risk of OC and OPC combined (OR 0.7, 95%CI 0.5, 1.0, p=

0.006). A series of pleiotropy-robust and outlier detection methods showed that pleiotropy

did not bias our findings.

Conclusion

We found limited evidence for a role of cholesterol-lowering in OC and OPC risk,

suggesting previous observational results may have been confounded. There was some

evidence that genetically-proxied inhibition of PCSK9 increased risk, while lipid-lowering

variants in LDLR, reduced risk of combined OC and OPC. This result suggests that the

mechanisms of action of PCSK9 on OC and OPC risk may be independent of its cholesterol

lowering effects, but further replication of this finding is required.

Author summary

Why was this study done?

- To determine if genetically-proxied cholesterol-lowering drugs (such as statins which target HMGCR) reduce oral and oropharyngeal cancer risk.

- To determine if genetically-proxied circulating lipid traits (e.g. low-density lipoprotein cholesterol) have a causal effect on oral and oropharyngeal cancer risk.

What did the researchers do and find?

- There was little evidence that genetically-proxied inhibition of HMGCR (target of statins), NPC1L1 (target of ezetimibe) and CETP (target of CETP inhibitors) influences oral or oropharyngeal cancer risk.

- There was little evidence of an effect of circulating lipid traits on oral or oropharyngeal cancer risk.

- There was some evidence that genetically-proxied inhibition of PCSK9 increases, while lipid-lowering variants in LDLR reduces oral and oropharyngeal cancer risk .

What do these findings mean?

- These findings suggest that the results of previous observational studies examining the effect of statins on oral and oropharyngeal risk may have been confounded.

- Given we found little evidence of an effect of other cholesterol lowering therapies, the mechanism of action of PCSK9 may be independent of cholesterol-lowering. Further replication of this finding in other head and neck cancer datasets is required.

Introduction

Head and neck squamous cell carcinoma (HNSCC), which includes cancers of the oral cavity (OC) and oropharynx (OPC), is the sixth most common cancer in the world, with over 550,000 new cases and 300,000 deaths annually [1, 2]. Despite some modest improvements in the treatment of HNSCC, survival ranges between 19 - 59% at 10 years [3] and recurrence rates remain high [4]. Patients often undergo a combination of surgery, radiotherapy and chemotherapy which can result in significant morbidity [5]. Established risk factors include smoking, alcohol and human papilloma virus (HPV), the latter mainly linked with oropharyngeal cancer [6, 7]. Given that in contemporary cohorts, around 70% of OPC cases (versus <5% of OC cases) are HPV driven and often present in younger populations, oral and oropharyngeal tumours are considered distinct disease entities, with different risk factor profiles [8]. Despite smoking cessation, alcohol reduction measures and the implementation of HPV vaccination in some areas, HNSCC remains a major global health problem [2]. Novel strategies for prevention of HNSCC are required, in particular for those at high risk and one approach is to identify novel risk factors which can be easily modified, for example by repurposing existing drugs [9].

Statins are one of the most commonly prescribed medications worldwide. They are prescribed to reduce levels of circulating total and low-density lipoprotein cholesterol (LDL-C), with proven preventative and therapeutic effects in cardiovascular disease and a good safety profile [10, 11]. Statins inhibit 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase (HMGCR)), the rate-limiting enzyme in the mevalonate pathway, responsible for cholesterol and steroid hormone synthesis [12]. Other clinically approved

drugs that target cholesterol metabolism via different mechanisms include ezetimibe

(targeting Niemann-Pick C1-like protein (NPC1L1)) and proprotein convertase subtilisin/kexin

type 9 (PCSK9) inhibitors such as evolocumab or alirocumab. These agents act by reducing the

intestinal absorption of cholesterol or by enhancing uptake of LDL-C through increased

cellular membrane expression of the LDL-receptor (LDLR), respectively. Conversely,

cholesteryl ester transfer protein inhibitors (CETP) substantially increase levels of high-density

lipoprotein cholesterol (HDL-C), lower levels of LDL-C and enhance reverse cholesterol

transport [13].

Cholesterol is vital for a variety of key cellular functions, including membrane integrity,

signalling, protein synthesis and cell cycle progression. Therefore, modulation of cholesterol

synthesis has the potential to influence several hallmarks of tumourigenesis including cell

migration and proliferation [14]. In an experimental study, mice given oral daily doses of

simvastatin two weeks prior to subcutaneous injection of FaDu (HPV-negative

hypopharyngeal tumour cells), showed a significant reduction in tumour growth. This study

was designed to mimic a clinical scenario where patients who present with a tumour may

have been taking the medication prior to tumour initiation [15], and suggested that

simvastatin antagonises tumour metabolic reprogramming, another important hallmark of

cancer [15]. Mechanistic support for the role of LDL-C lowering in cancer development comes

largely from the fact that lipids are themselves major cell membrane components essential

for cell division and maintaining tissue integrity. Changes in lipid levels have been reported

associated with tumour development [16, 17].

However, the evidence that cholesterol-lowering drugs may reduce the risk of head

and neck cancer is limited. Some observational studies report an inverse association of taking

statins with both head and neck cancer risk and survival [14, 18], but others indicate little

evidence of any effect [19]. Observational studies are not randomised and are susceptible to

reverse causality and/or confounding [19]. Mendelian randomization (MR) is an approach

that uses germline genetic proxies (referred to as instruments) to help appraise causal effects

of potentially modifiable extrinsic exposures or intrinsic traits with disease [20-22]. It has also

been used to estimate therapeutic potential by investigating genetic variation at drug targets

[23]. Numerous single nucleotide polymorphisms (SNPs) are associated with lower levels of

circulating LDL-C [24, 25] and inheriting an LDL-C lowering allele has been proposed to be

analogous to being assigned life-long treatment with a cholesterol lowering drug [26]. In this

way, germline genetic variants may serve as proxies for exposure to potential

pharmacological agents which are less likely than observational measures to be subject to

reverse causation or confounding. Genetic proxies can therefore be used to predict both the

likely beneficial and adverse effects of long-term modulation of the drug targets on disease.

MR has previously demonstrated the protective effect of cholesterol-lowering drugs

on cardiovascular disease risk [27] , but also that inhibition of HMGCR and PCSK9 may have

an adverse effect on diabetes risk [28]. Of relevance to cancer, some recent MR studies have

shown that genetically-proxied inhibition of HMGCR may be protective against overall cancer

[29] and epithelial ovarian cancer [30] risk. Our aim was to use MR to appraise the causal

nature and mechanistic basis of the relationship between cholesterol-lowering and risk of oral

and oropharyngeal cancer by investigating germline variation in HMGCR, NPC1L1, CETP,

PCSK9 and LDLR, and other related lipid traits such as circulating LDL-C.

Methods

Identifying cholesterol-lowering genetic instruments. For the primary analysis, SNPs in

HMGCR, *NPC1L1*, *CETP*, *PCSK9* and *LDLR* were used to proxy the effect of lipid-lowering

therapies and to estimate the downstream effect of manipulating these targets on OC and

OPC risk. SNPs were identified within 100 kb on either side of the target gene (*HMGCR*,

NPC1L1, *CETP, PCSK9* and *LDLR)* that were associated with LDL-C levels. Variants were robustly

associated with LDL-C in a meta-analysis of genome-wide association studies (GWAS)

involving 188,578 individuals primarily (96%) of European ancestry in the Global Lipids

Genetic Consortium (GLGC) [25]. Linkage disequilibrium (LD) (r^2) was evaluated to check the

overlap between variants using LDmatrix (4.0 Release) [31]. Proxy SNPs were permitted to be

in weak LD ($r^2 < 0.2$) with each other, to increase the proportion of variance explained in each

respective drug target therefore maximising instrument strength. Multiple papers have used

these genetic instruments at this threshold, to demonstrate causal effects in cardiovascular

disease [13, 27, 32], diabetes [28] and ovarian cancer [30]. In secondary analyses, SNPs were

used to proxy circulating levels of LDL-C, HDL-C, total triglyceride, total cholesterol,

apolipoprotein A and B. Betas represented the change in lipid trait levels per copy of the effect

allele. These SNPs were already independently ($r^2 < 0.001$) associated with the respective traits

in large GWAS which have been described previously [25, 33].

Summary level genetic data on oral and oropharyngeal cancer from GAME-ON.

We estimated the effects of the cholesterol-lowering genetic variants on risk of OC and OPC

using GWAS performed on 6,034 cases and 6,585 controls from 12 studies which were part of

the Genetic Associations and Mechanisms in Oncology (GAME-ON) Network [34]. The study

population included participants from Europe (45.3%), North America (43.9%) and South

America (10.8%). Cancer cases comprised the following the International Classification of

Diseases (ICD) codes: oral cavity (C02.0-C02.9, C03.0-C03.9, C04.0-C04.9, C05.0-C06.9)

oropharynx (C01.9, C02.4, C09.0-C10.9), hypopharynx (C13.0-C13.9), overlapping (C14 and

combination of other sites) and 25 cases with unknown ICD code (other). A total of 954

individuals with cancers of hypopharynx, unknown code or overlapping cancers were

excluded. Genomic DNA isolated from blood or buccal cells was genotyped at the Center for

Inherited Disease Research (CIDR) using an Illumina OncoArray custom designed for cancer

studies by the OncoArray Consortium [35]. In GAME-ON, all SNPs with a call rate of <95% were

excluded. Given the ethnic heterogeneity of the study population, the dataset was divided by

geographical region and SNPs within each region that showed deviation from Hardy-

Weinberg Equilibrium (HWE) in controls (p= <1 x10^{-7}) were excluded. Principal component

analysis (PCA) was performed using approximately 10,000 common markers in low LD

(r^2 <0.004), minor allele frequency (MAF) >0.05 and 139 population outliers were removed.

Full details of the included studies, as well as the genotyping and imputation performed, have

been described previously [34, 36].

Two-sample Mendelian randomization. Two-sample MR was conducted using the

"TwoSampleMR" package in R (version 3.5.3), by integrating SNP associations for cholesterol-

lowering (sample 1) with those for OC and OPC in GAME-ON (sample 2). For those SNPs

instrumenting LDL-C lowering, we first extracted summary statistics for the associations with

OC and OPC from GAME-ON. We next performed harmonisation of the direction of effects

between the cholesterol-lowering exposures and outcome (OC or OPC) where, for each

variant, the allele designated the 'exposure allele' was associated with lower LDL-C levels and

palindromic SNPs were aligned when MAFs were <0.3 or were otherwise excluded. In our

primary analysis, four palindromic SNPs, one in *HMGCR* (rs2006760), the other in *PCSK9*

(rs2149041) and two in *CETP* (rs5880, rs9929488) were removed. In the secondary analysis

with other lipid traits, 11 palindromic SNPs (rs1936800, rs2288912, rs7112577, rs964184,

rs150617279, rs1883711, rs4722043, rs2156552, rs2954029, rs581080, rs7534572) were

removed.

Individual effect-estimates for each SNP were calculated using the Wald ratio, by

dividing the SNP-outcome association by the SNP-exposure association. Multiple SNPs were

then combined into multi-allelic instruments using the random-effects inverse-variance

weighted (IVW) meta-analysis method, for each of the genes *HMGCR, NPC1L1, CETP, PCSK9*

and *LDLR.* This meta-analysis was undertaken to increase the proportion of variance in drug

targets and LDL-C lowering explained by each instrument, and thus improve statistical power

and the precision of our estimates [37]. The analysis produced an estimate of the effect of

the risk factor on OC and OPC risk. As the instruments for *HMGCR*, *NPC1L1, CETP, PCSK9* and

LDLR were in weak LD (r^2 <0.2), we accounted for this correlation between SNPs in the primary

analysis using LDlink (4.0 Release) which employs Phase 3 (Version 5) of the 1000 Genomes

Project and variant rs numbers based on dbSNP. Correlation matrices were inserted as an

MRInput object [31], resulting in MR methods which altered the weightings for correlated

SNPs [38-40]. For circulating lipid traits, a more stringent r^2 <0.001 was already applied in the

initial GWAS [25], so we did not account further for correlation in the secondary analysis. We

computed odds ratios (OR) which represent the change in odds of oral and oropharyngeal

squamous cell carcinoma per genetically-proxied inhibition of the drug target, equivalent to

a 1 mg/dl decrease in LDL-C. The OR was scaled to be per 1 mmol/L decrease by dividing the

LDL-C lowering effect (beta) and standard error (se) measured in mg/dL by 38.7 [30]. The

betas and standard errors for *HMGCR*, *NPC1L1*, *CETP*, *PCSK9* and *LDLR* SNPs were also

converted to reflect the cholesterol-lowering effect, given the "TwoSampleMR" package

preference to automatically change these into a positive direction of effect (i.e. lipid

increasing). The correct direction of effect was checked using a positive control of coronary

heart disease from the CARDIoGRAM GWAS data [41]. MR was also used to examine the effect

of circulating levels of LDL-C, HDL-C, total triglyceride, total cholesterol, apolipoprotein A and

B levels directly with OC and OPC cancer risk. The ORs in this analysis represent the change in

odds of oral or oropharyngeal squamous cell carcinoma, per SD unit increase in lipid trait.

The IVW method can provide an unbiased effect estimate in the absence of horizontal

pleiotropy or when horizontal pleiotropy is balanced [42]. We therefore performed sensitivity

analyses to evaluate the potential for unbalanced horizontal pleiotropy, where genetic

variants influence two or more traits through independent biological pathways. To ensure the

genetic instrument was associated with the instrument it was proxying, estimates of the

proportion of variance in each risk factor explained by the instrument (R^2) and F-statistics

were generated. An F-statistic of <10 is indicative of a weak instrument which may be subject

to weak instrument bias. To account for directional pleiotropy, we compared the IVW results

with three MR sensitivity analyses, which each make different assumptions: MR Egger [43],

weighted median [44] and weighted mode [45]. While these three methods are best used

when genetic instruments consist of a large numbers of independent SNPs, since r^2 values

between SNPs in our instruments were low (r^2 <0.2), we a-priori decided to include them, with

a further sensitivity analysis to account for correlation in the MR Egger analysis. The weighted

median stipulates that at least 50% of the weight in the analysis stems from variants that are

valid instruments [44], while the weighted mode requires that the largest subset of

instruments which identify the same causal effect to be valid instruments [45]. MR-Egger can

provide unbiased estimates even when all SNPs in an instrument violate the exclusion

restriction assumption (i.e. affect the outcome by means other than via the risk factor of

interest). However, there must be negligible measurement error (NOME) [46] in the genetic

instrument and the InSIDE (Instrument Strength Independent of Direct Effect) assumption

must be satisfied [43]. Where there was evidence of violation of the NOME assumption, this

was assessed using the I^2 statistic and MR-Egger was performed with simulation extrapolation

(SIMEX) correction [46]. To further assess the robustness of findings, we examined evidence

of heterogeneity in the individual SNP estimates using the Cochran Q-statistic, which may

indicate the presence of invalid instruments (e.g. due to horizontal pleiotropy) [47]. Scatter

and leave-one-out plots were produced to evaluate influential outliers and MR-PRESSO

(Mendelian Randomization Pleiotropy RESidual Sum and Outlier) was used to detect and

correct for potential outliers (where Q-statistic $p < 0.05$) [48].

Stratification by cancer subsite. Given the difference in established aetiology (i.e. smoking,

alcohol and HPV) at each HNSCC subsite [6], we performed MR analyses with stratification by

cancer subsite to evaluate potential heterogeneity in effects. For this, we used GWAS

summary data on a subset of 2,641 OPC cases and 2,990 OC cases from the 6,034 HNSCC cases

and the 6,585 common controls in the GAME-ON GWAS [34].

Replication in UK Biobank. UK Biobank data was used as a replication dataset for primary

analyses. A GWAS was performed on 839 combined OC and OPC cases and 372,016 controls,

with two further stratified GWAS for OC (n= 357) and OPC (n= 494). UK Biobank is a large

population-based cohort study that recruited over 500,000 men and women aged between

37 and 73 years between 2006 and 2010 throughout the UK. It received ethical approval from

the National Health Service North West Centre for Research Ethics Committee (reference:

11/NW/0382). Details of genotyping quality control, phasing and imputation are described

elsewhere [49]. Participant records are linked to cancer registry data and HNSCC was grouped

using the same ICD-codes as described above. Squamous cell carcinoma cases were identified

using histology codes 8070 – 8078. UK Biobank GWAS analyses were adjusted for sex and

genotyping array and performed in BOLT-LMM, a mixed model that accounts for population

stratification and relatedness [50, 51]. Primary MR analyses as described above in GAME-ON

were repeated in UK Biobank data.

Meta-analysis of results. We performed both fixed-effects and random-effects meta-analysis

of the MR estimates in GAME-ON and UK Biobank using the R package 'meta'. However, we

focus more on the fixed-effects estimates since we assume that the causal effect is constant

between the studies [52]. Heterogeneity between study populations was assessed using I^2

statistic [53].

Results

Primary analysis in GAME-ON. In total, 5 SNPs in *HMGCR* (rs12916, rs17238484, rs5909,

rs2303152, rs10066707) were used to proxy HMG-CoA reductase inhibition (statins); 5 SNPs

in *NPC1L1* (rs217386, rs2073547, rs7791240, rs10234070, rs2300414) proxied NPC1L1

inhibition (ezetimibe); 6 SNPs in *CETP* (rs9989419, rs12708967, rs3764261, rs1800775,

rs1864163, rs289714) proxied CETP inhibition; 6 SNPs in *PCSK9* (rs11206510, rs2479409,

rs2479394, rs10888897, rs7552841, rs562556) proxied PCSK9 inhibition; 3 SNPs proxied

cholesterol-lowering in *LDLR* (rs6511720, rs1122608, rs688) (LDL-receptor inhibition). Further

details of these SNP effects are given in **Table 1**.

Table 1. Detailed summary of LDL-C lowering genetic variants in *HMGCR*, *NPC1L1*, *CETP*,

PCSK9 and *LDLR* variants from the in Global Lipids Genetics Consortium (GLGC)

Target	SNP	Pathway	EA	OA	EAF	Beta	se	*P*-value
HMGCR	rs12916	LDL-C	T	C	0.57	-0.06061	0.003	7.79E-78
	rs17238484	LDL-C	G	T	0.75	-0.05184	0.005	1.35E-21
	rs5909	LDL-C	G	A	0.90	-0.05102	0.007	4.93E-13
	rs2303152	LDL-C	G	A	0.88	-0.03498	0.005	1.04E-09
	rs10066707	LDL-C	G	A	0.58	-0.0411	0.005	2.97E-19
	rs2006760*	LDL-C	C	G	0.81	-0.04407	0.006	1.67E-13
NPC1L1	rs217386	LDL-C	A	G	0.41	-0.02908	0.003	1.20E-19
	rs2073547	LDL-C	A	G	0.81	-0.03885	0.004	1.92E-21
	rs7791240	LDL-C	T	C	0.91	-0.03404	0.005	1.84E-10
	rs10234070	LDL-C	C	T	0.90	-0.02363	0.005	1.52E-06
	rs2300414	LDL-C	G	A	0.93	-0.02828	0.006	5.45E-06
CETP	rs3764261	LDL-C	A	C	0.29	-0.04471	0.004	2.22E-34
	rs1800775	LDL-C	A	C	0.48	-0.03487	0.003	8.54E-24
	rs1864163	LDL-C	G	A	0.73	-0.03698	0.004	7.97E-21
	rs9929488*	LDL-C	G	C	0.70	-0.03159	0.004	8.15E-13
	rs9989419	LDL-C	G	A	0.60	-0.02344	0.004	2.49E-12
	rs12708967	LDL-C	T	C	0.80	-0.02963	0.004	3.47E-11
	rs289714	LDL-C	A	G	0.79	-0.03032	0.005	2.85E-10
	rs5880*	LDL-C	G	C	0.94	-0.03979	0.008	1.59E-06
PCSK9	rs11206510	LDL-C	C	T	0.15	-0.06871	0.001	2.38E-53
	rs2479409	LDL-C	A	G	0.67	-0.05309	0.001	2.52E-50
	rs2149041*	LDL-C	C	G	0.84	-0.05259	0.001	1.44E-35
	rs2479394	LDL-C	A	G	0.72	-0.03192	0.001	1.58E-19
	rs10888897	LDL-C	T	C	0.40	-0.04192	0.001	8.43E-31
	rs7552841	LDL-C	C	T	0.63	-0.04589	0.001	5.40E-15
	rs562556	LDL-C	G	A	0.19	-0.05292	0.002	6.16E-21
LDLR	rs6511720	LDL-C	T	G	0.11	-0.17482	0.004	3.69E-54
	rs1122608	LDL-C	T	G	0.23	-0.05473	0.003	2.02E-86
	rs688	LDL-C	C	T	0.56	-0.04465	0.003	3.04E-48

EA, effect allele or low-density lipoprotein-cholesterol (LDL-C) lowering allele; OA = other or non-

effect allele; EAF, effect allele frequency; se= standard error. * Palindromic SNPs removed

Beta represents the change in LDL-C levels per copy of the effect allele. For SI conversion of mmol/L

to mg/dL, multiply by 38.7.

There was limited evidence of an effect of genetically-proxied inhibition of HMGCR

and NPC1L1 on combined OC and OPC risk (OR IVW 1.1; 95%CI 0.6, 1.9, p= 0.82 and 1.0; 95%

CI 0.4, 2.7, p= 0.99), respectively. (**Table 2** and **S1 Fig**). A similar result was found for

genetically-proxied LDL-C lowering inhibition of CETP on OC and OPC combined (OR IVW 1.3;

95%CI 0.6, 2.6, p= 0.49) (**Table 2 and S1 Fig**). However, higher risk of combined OC and OPC

was found in relation to genetically-proxied PCSK9 inhibition, equivalent to a 1 mmol/L (38.7

mg/dL) reduction in LDL-C (OR IVW 2.1; 95%CI 1.2, 3.4, p= 0.01; **Table 2 and Fig 1**). This is in

contrast to the reduction in odds seen in relation to cardiovascular disease using the same

instrument (OR IVW 0.6; 95%CI 0.4, 0.8, p <1 x10^{-03}; **Fig 2**) in 60,801 cases and 123,504 control

subjects enrolled in the CARDIoGRAM consortia studies [41]. There was also some evidence

that LDLR variants, resulting in genetically-proxied reduction in LDL-C equivalent to a 1

mmol/L (38.7 mg/dL), reduced the risk of combined OC and OPC (OR IVW; 0.7; 95%CI 0.4, 1.0,

p= 0.05; **Table 2, Fig 1**).

Fig 1. Forest plot showing the causal effects of *HMGCR, NPC1L1, CETP, PCSK9* and *LDLR*

variants on the oral and oropharyngeal cancer subsites in GAME-ON. Effect estimates on

oral and oropharyngeal cancer are reported on the log odds scale.

Fig 2. Forest plots showing the causal effects of cholesterol-lowering PCSK9 and LDLR single

nucleotide polymorphisms on coronary heart disease and combined oral/ oropharyngeal

cancer in GAME-ON. Effect estimates on oral and oropharyngeal cancer are reported on the

log odds scale.

Table 2. Mendelian randomization results of genetically-proxied inhibition of HMGCR, NPC1L1, CETP, PCSK9 and LDLR with risk of oral and

oropharyngeal cancer including sensitivity analyses in GAME-ON

	Outcome	Exposure/ Outcome dataset	Outcome N	Number of SNPs	IVW		Weighted median		Weighted mode		MR-Egger	
					OR (95%CI)	P	OR (95%CI)	P	OR (95%CI)	P	OR (95%CI)	P
HMGCR	Oral/ Oropharyngeal cancer	GAME-ON/ GLGC	6,034	5	1.07 (0.62, 1.84)	0.82	1.20 (0.63, 2.28)	0.58	1.20 (0.57, 2.50)	0.66	1.33 (0.07, 26.58)	0.86
	Oral cancer	GAME-ON/ GLGC	2,990	5	1.49 (0.75, 2.96)	0.25	1.66 (0.73, 3.78)	0.23	1.69 (0.65, 4.42)	0.35	1.25 (0.03, 55.80)	0.91
	Oropharyngeal cancer	GAME-ON/ GLGC	2,641	5	0.90 (0.43, 1.85)	0.77	1.01 (0.43, 2.34)	0.99	1.08 (0.44, 2.64)	0.88	0.77 (0.01, 45.07)	0.91
NPC1L1	Oral/ Oropharyngeal cancer	GAME-ON/ GLGC	6,034	5	1.01 (0.38, 2.69)	0.99	0.90 (0.29, 2.82)	0.86	0.86 (0.24, 3.08)	0.83	0.22 (0.00, 102.42)	0.66
	Oral cancer	GAME-ON/ GLGC	2,990	5	1.02 (0.30, 3.41)	0.98	1.20 (0.29, 5.05)	0.80	1.29 (0.22, 7.41)	0.79	0.09 (0.00, 160.66)	0.57
	Oropharyngeal cancer	GAME-ON/ GLGC	2,641	5	0.60 (0.16, 2.25)	0.45	0.60 (0.12, 3.04)	0.53	0.60 (0.10, 3.73)	0.62	0.20 (0.01, 688.64)	0.72
CETP	Oral/ Oropharyngeal cancer	GAME-ON/ GLGC	6,034	6	1.28 (0.64, 2.55)	0.49	1.24 (0.54, 2.81)	0.61	1.25 (0.43, 3.64)	0.71	0.82 (0.02, 27.60)	0.92
	Oral cancer	GAME-ON/ GLGC	2,990	6	1.65 (0.70, 3.88)	0.25	1.69 (0.61, 4.70)	0.31	1.63 (0.43, 5.87)	0.49	0.42 (0.01, 32.58)	0.72
	Oropharyngeal cancer	GAME-ON/ GLGC	2,641	6	1.12 (0.45, 2.77)	0.81	1.05 (0.35, 3.20)	0.93	0.73 (0.17, 3.07)	0.69	1.50 (0.02, 142.22)	0.87

				N	IVW OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P
PCSK9	Oral/ Oropharyngeal cancer	GAME-ON/ GLGC	6,034	6	2.05 (1.24, 3.38)	0.01	2.21 (1.12, 4.08)	0.01	2.19 (0.81, 5.92)	0.18	1.83 (0.17, 20.00)	0.65
	Oral cancer	GAME-ON/ GLGC	2,990	6	1.62 (0.89, 2.94)	0.11	1.80 (0.90, 3.62)	0.10	2.00 (0.73, 5.48)	0.23	2.17 (0.15, 32.13)	0.60
	Oropharyngeal cancer	GAME-ON/ GLGC	2,641	6	3.49 (1.58, 7.68)	2.00 E-03	3.19 (1.40, 7.26)	0.01	2.73 (0.86, 8.70)	0.15	1.99 (0.04, 92.11)	0.74
LDLR	Oral/ Oropharyngeal cancer	GAME-ON/ GLGC	6,034	3	0.65 (0.42, 1.00)	0.05	0.71 (0.47, 1.08)	0.11	0.74 (0.47, 1.15)	0.31	0.90 (0.41, 1.95)	0.83
	Oral cancer	GAME-ON/ GLGC	2,990	3	0.53 (0.32, 0.87)	0.01	0.56 (0.32, 0.98)	0.04	0.57 (0.32, 1.04)	0.21	0.56 (0.18, 1.76)	0.50
	Oropharyngeal cancer	GAME-ON/ GLGC	2,641	3	0.90 (0.53, 1.52)	0.69	0.91 (0.55, 1.53)	0.73	1.08 (0.62, 1.89)	0.81	1.56 (0.64, 3.82)	0.51

Abbreviations: IVW, inverse variance weighted; OR, odds ratio; CI, confidence intervals; P, *p*-value.

OR represents the exponential change in odds of oral/ oropharyngeal squamous cell carcinoma per genetically-proxied inhibition of drug target equivalent

to a 1 mmol/L decrease in LDL-C.

Stratification by cancer subsite in GAME-ON. When stratified by subsite, the adverse

effect of PCSK9 appeared to be mainly in the oropharynx, (OR IVW 3.5; 95%CI 1.6, 7.7, p= 2

$\times 10^{-03}$), with limited evidence in the oral cavity (OR IVW 1.6; 0.9, 2.94, p= 0.11) (**Table 2 & Fig**

1). The effects appeared stronger in OPC versus OC, but with overlapping confidence intervals.

LDLR was associated with a reduction in risk of OC (OR IVW 0.5; 95%CI 0.3, 0.9, p= 0.01), but

there was little evidence of an association with OPC (OR IVW 0.9; 95%CI 0.5, 1.5, p= 0.69)

(**Table 2 and Fig 1**). For both PCSK9 and LDLR associations, the direction of effect was generally

consistent across the four MR methods tested (**Table 2**).

Secondary analysis in GAME-ON. SNPs were also used to proxy circulating levels of LDL-C (77

SNPs), high-density lipoprotein cholesterol (HDL-C) (85 SNPs), total triglyceride (54 SNPs),

total cholesterol (82 SNPs), apolipoprotein A (9 SNPs) and apolipoprotein B (14 SNPs) (**S1**

Table). There was limited evidence of an effect of any of these other lipid traits on either OC

or OPC (**Table 3 and S2 Fig**).

434   **Table 3.** Mendelian randomization results of circulating lipid traits with risk of oral and

435   oropharyngeal cancer in GAME-ON

Target	N SNPs	Outcome	IVW OR (95% CI)	*P*-value
LDL-C	77	Oral/ Oropharyngeal cancer	0.98 (0.87, 1.11)	0.79
		Oral cancer	0.99 (0.85, 1.15)	0.88
		Oropharyngeal cancer	1.03 (0.87, 1.21)	0.76
HDL-C	85	Oral/ Oropharyngeal cancer	0.98 (0.83, 1.16)	0.79
		Oral cancer	1.08 (0.88, 1.32)	0.45
		Oropharyngeal cancer	0.87 (0.71, 1.05)	0.15
Total triglycerides	54	Oral/ Oropharyngeal cancer	1.19 (1.01, 1.04)	0.04
		Oral cancer	1.19 (0.96, 1.46)	0.11
		Oropharyngeal cancer	1.19 (0.96, 1.47)	0.12
Total cholesterol	82	Oral/ Oropharyngeal cancer	1.04 (0.91, 1.18)	0.55
		Oral cancer	1.09 (0.93, 1.28)	0.30
		Oropharyngeal cancer	1.00 (0.84, 1.20)	0.96
Apolipoprotein A	9	Oral/ Oropharyngeal cancer	0.87 (0.73, 1.03)	0.11
		Oral cancer	0.90 (0.73, 1.12)	0.34
		Oropharyngeal cancer	0.82 (0.65, 1.04)	0.10
Apolipoprotein B	14	Oral/ Oropharyngeal cancer	1.04 (0.88, 1.22)	0.67
		Oral cancer	1.15 (0.89, 1.49)	0.29
		Oropharyngeal cancer	1.00 (0.83, 1.21)	0.98

Abbreviations: IVW, inverse variance weighted; OR, odds ratio; CI, confidence intervals.

IVW OR represents the exponential change in odds of oral/ oropharyngeal squamous cell carcinoma
per SD increase in the circulating lipid trait (one SD for LDL-C = 38.7 mg/dL, HDL-C = 15.5 mg/dL,
Apolipoprotein A = 0.32 g/L, Apolipoprotein B = 0.52 g/L, Total triglycerides = 90.7 mg/dL, Total
cholesterol = 41.8 mg/dL).

Sensitivity analyses. IVW, MR Egger, weighted median, simple and weighted mode were

carried out, in addition to IVW analysis accounting for LD structure (**S2.1-2.5 Tables**). The

results adjusting for SNP correlation followed the same pattern as the main results (**S3 Table**).

There was limited evidence of weak instrument bias being present (F-statistic >10) and the

proportion of variance in the phenotype (R^2) explained by the genetic instruments ranged

from 0.1 to 6% (**S4 Table**). In both primary and secondary analyses there was limited evidence

of heterogeneity in the SNP effect estimates for IVW and MR Egger regression, except for in

HDL-C (Q IVW 115.7, p= 0.01; Q MR Egger 115.6, p= 0.01) (**S5 and S6 Tables**).

MR Egger intercepts also indicated limited evidence of directional pleiotropy (**S7 and**

S8 Tables). For the primary analysis there were no clear outliers in both scatter and leave-

one-out plots (**Fig 3 and S3-6 Figs**) and MR-PRESSO detected no individual outliers (**S9 Table**).

Where there was evidence of violation of the NOME assumption for the HMGCR, NPC1L1 and

CETP instruments (i.e. I^2 statistic <0.90) (**S10 Table**), MR-Egger was performed with SIMEX

correction and effects were still consistent with the null (**S11 Table**).

Fig 3. Scatter plots for LDLR and PCSK9 single nucleotide polymorphisms effect on combined

oral/ oropharyngeal cancer in GAME-ON.

Replication in UK Biobank and meta-analysis of results. Primary MR analyses as described

above were replicated in UK Biobank, showing limited evidence of an effect of genetically-

proxied inhibition of HMGCR, NPC1L1, CETP, PCSK9 and LDLR on risk of OC and OPC (**S12**

Table). Following IVW fixed-effects meta-analysis of GAME-ON and UK Biobank MR results,

there was a consistently strong effect of genetically-proxied PSCK9 inhibition on combined

OC and OPC (OR IVW 1.8; 95%CI 1.2, 2.8), with good concordance between studies (I^2= 22%)

and methods used (**Fig 4** and **S7 Fig**). Effects for PCSK9 appeared stronger in relation to OPC

(OR IVW 2.6; 95%CI 1.4, 4.9) than OC (OR IVW 1.4; 95%CI 0.8, 2.4), but with moderate

heterogeneity between studies (I^2= 41%) (**Fig 4**). Conversely, the protective effect for LDLR on

OC and OPC combined was also consistent in the meta-analysis (OR IVW 0.7; 95%CI 0.5, 1.0),

with good concordance between studies (I^2= 0%) (**Fig 5** and **S7 Fig**). However, the protective

effect seen specifically in relation to OC in GAME-ON (OR IVW 0.5; 95%CI 0.3, 0.9) was not

replicated in UK Biobank (OR IVW 1.6; 95%CI 0.5, 4.8), with strong evidence of heterogeneity

between the studies (I^2= 66%).

Fig 4. Forest plots showing inverse variance weighted meta-analysis effects of cholesterol-

lowering *PCSK9* single nucleotide polymorphisms on head and neck cancer subsites.

Fig 5. Forest plots showing inverse variance weighted meta-analysis effects of cholesterol-

lowering *LDLR* single nucleotide polymorphisms on head and neck cancer subsites.

Discussion

We found limited evidence for a role of cholesterol-lowering in OC and OPC risk. This

included the absence of a protective effect of genetically-proxied inhibition of HMGCR,

suggesting previous observational studies investigating the relationship between statins and

head and neck cancer risk may be subject to residual confounding or bias. However, we did

observe an adverse effect of PCSK9 inhibition on OC and OPC risk, which was of a similar

magnitude to the protective effect seen in relation to cardiovascular disease using the same

genetic instrument (**Fig 2**). This PCSK9 effect was evident in both the GAME-ON (n= 6,034 OC

and OPC cases and n= 6,585 controls) and UK Biobank datasets (n= 839 OC and OPC cases and

n= 372,016 controls). We also found some evidence for a protective effect of cholesterol-

lowering variants in *LDLR* on OC and OPC risk in both studies. The IVW analysis for HMGCR,

NPC1L1, CETP, PCSK9 and LDLR accounting for LD structure (r^2 <0.2) followed the same

pattern as the main results (**S3 Table**).

Association between PCSK9, LDLR and cancer risk. Despite the lack of consistent evidence

for a role of cholesterol-lowering on risk of OC or OPC in this study, individual effects of both

PCSK9 and LDLR were demonstrated which may implicate a role for these drug targets in the

development of OC or OPC via other mechanisms. The effects identified in the present study

are directionally consistent with a recent MR analysis of 1,615 combined head and neck

cancer cases from UK Biobank, which also found that a 1 SD unit increase in LDL-C proxied by

PCSK9 and LDLR was associated with a reduction (OR 0.7 95%CI 0.4, 1.4, p= 0.35) and increase

in odds (OR 1.6 95%CI 1.0, 2.4, p= 0.05) of head and neck cancer, respectively [29]. The

opposing effects of PCSK9 and LDLR in this study also suggests that cholesterol lowering is

unlikely to be the main mechanism of action. However, this previous analysis is limited by the

relatively small number of cases and heterogeneity of head and neck cancer subtypes, with

no selection for the histological subtype of squamous cell carcinoma. In the present study, we

focused specifically on oral and oropharyngeal subtypes of HNSCC.

Beyond the established role of *PCSK9* in cholesterol homeostasis, other potential

pleiotropic effects are not well understood. Variants in *PCSK9* have been associated with an

increased risk of diabetes (OR 1.1, 95%CI 1.0, 1.2 for each 10 mg per decilitre decrease in LDL-

C) [28]. However, a recent phenome-wide association study (PheWAS) did not find *PCSK9*

or *LDLR* to be correlated with any non-lipid-related phenotypes, including diabetes [54].

There is limited *in vivo* and *in vitro* evidence that *PCSK9* might be involved in both cell

proliferation and apoptosis. The gene was initially designated as NARC1 (neural apoptosis-

regulated convertase 1), involved in apoptosis of cerebellar neurons [55] and *PCSK9* has since

been found to be upregulated in some cancers [56, 57].

One suggested mechanism for a link with cancer progression is that the increased

expression of *PCSK9* prevents LDL-receptor (LDLR) recycling, leading to

hypercholesterolaemia and more exogenous lipid to support the proliferation of the tumour

[55]. Our study suggests the opposite, that genetically-proxied inhibition of *PCSK9* results in

an increased risk of OC or OPC. We hypothesise that access to intracellular LDL-C could in fact

be pro-tumourigenic, providing a favourable environment for a developing tumour cell,

maintaining membrane integrity and promoting cell division. Therapies such as statins,

ezetimibe, and PCSK9 inhibitors may all lower LDL-C level through the upregulation of LDL-

receptors, resulting in elevated intracellular cholesterol. However, cancer mechanisms are

often context dependent and perhaps only the expression of *PCSK9* and *LDLR* is relevant in

head and neck cancer. CETP inhibitors instead block the transfer of cholesteryl ester from

HDL-C to LDL-C, thereby raising HDL-C and lowering LDL-C (and apolipoprotein B), as well as

enhancing reverse cholesterol transport [58]. Unlike statins, CETP inhibitors do not appear to

increase the risk of type 2 diabetes, thought to be as a result of pancreatic islet cell cholesterol

accumulation with use of other cholesterol-lowering drugs [59]. Therefore, the absence of

effect when proxying *CETP* inhibition in this study, supports the possible mechanism of LDL-C

uptake via the LDL-receptor in OC or OPC.

While both *PCSK9* [60] and *LDLR* [61] are expressed in head and neck tumours, this was not

evident in normal oral or oropharyngeal tissue, and sufficient tissue is currently not available

in expression datasets [62]. Recent studies have associated elevated *PCSK9* with alcohol use

disorder, including the interesting possibility of using anti-PSCK9 monoclonal antibodies for

the treatment of alcoholic liver disease [63, 64]. Given that alcohol is a well-known risk factor

for HNSCC, this pleiotropy could have partially explained the effect seen in our study, however

we proxied the inhibition of *PCSK9* and so would have expected to see a protective effect of

this gene in HNSCC cases who may have been heavy alcohol drinkers. Further investigation is

required to untangle the relationship between *PCSK9*, alcohol and head and neck cancer.

Comparison with previous studies. It is believed that statins could play a potential role in

cancer chemoprevention which may reduce the risk of some site-specific cancers such as

prostate [65] and ovarian [30], but not all. Some of these studies have reported cancer risk

reductions by as much as 50 – 65% [66-68]. However, meta-analyses and clinical trials have

contradicted these findings [69, 70]. In addition to confounding, immortal time bias likely

inflated observational results because, to be classified as a long-term statin user necessitates

that users survived without cancer over a long period [19, 71]. Dickerman et al. used

electronic records from 733,804 adults with 10-year follow-up to emulate a trial design. To

achieve this a pre-specified protocol was set, including eligibility criteria and checks were

made to ensure effect estimates for statins on cancer were comparable between the large

observational dataset and trial. The authors found little indication that statin therapy

influences cancer incidence, which was consistent with the analyses of randomised trials (with

a 10-year cancer-free survival difference of −0.3% 95%CI −1.5%, 0.5%) [19]. Nonetheless,

recent MR studies [29, 30] have identified an association between variants in *HMGCR* with

cancer risk, but not alternative cholesterol-lowering treatments or genetically-predicted LDL-

C, suggesting that statins may reduce cancer risk through a cholesterol independent pathway.

A recent case-control study of over 11,000 participants found an inverse association between

statin use and the occurrence of HNSCC (OR 0.86, 95%CI 0.77, 0.95, p= <0.01, of prior statin

exposure for cases compared to propensity score-matched controls) [18]. However, a wider

systematic review found that the evidence for the role of statins in the prevention of HNSCC

was limited [72]. As HNSCC incidence is a rare outcome, randomised controls trials are not

feasible, so we must be cautious interpreting the available observational findings given the

potential for bias and confounding as discussed previously.

In contrast to previous MR studies assessing overall cancer risk [29] and ovarian

specific risk [30], the MR carried out here in relation to OC and OPC showed no effect using

genetic instruments for HMGCR (statins). There was also limited evidence for a causal effect

of NPC1L1 (ezetimibe), CETP (CETP inhibitors) as well as a number of other circulating lipid

traits on OC or OPC. Therefore, it remains unclear as to whether the effects observed with

PCSK9 and LDLR are via LDL-C lowering or another less well-established pathway [73, 74], such

as receptor regulation for viral entry, synthesis of sex hormones and resultant dysregulated

metabolism [75-77].

Strengths and limitations of this study. Protective associations between cholesterol-lowering

therapies such as statins and head and neck cancer risk seen in previous observational studies

could be a result of reverse causation, immortal time bias, lack of randomisation or

confounding by socioeconomic status, smoking or HPV infection, for example. Our study

applied MR in an attempt to overcome these issues, using the largest number of SNPs

identified from the latest GWAS for both cholesterol-lowering and head and neck cancer that

could be identified in the literature [25, 34]. A series of pleiotropy-robust MR methods and

outlier detection were applied to rigorously explore the possibility that findings were not

biased as a result of pleiotropy. However, there was no HPV data available in these summary

results to enable more detailed stratified analysis of OPC. We did replicate findings for PCSK9

and LDLR, but the number of cases are low. Finally, most participants in the GAME-ON

network [34] were of European or North American decent, with only around 11% from South

America, and participants included in the UK Biobank analysis were exclusively of European

descent, so more work is required to determine if our results translate to other ancestry

groups.

In conclusion, our MR analyses provided little evidence for a role of cholesterol

lowering in OC or OPC risk although effects of genetically-proxied inhibition of *PCSK9* and

cholesterol-lowering variants in *LDLR* were observed in relation to OPC and OC risk. Given the

lack of a common pathway to carcinogenesis in OC or OPC, metabolic targets that may be

common to all tumours, regardless of the activated molecular pathway, could help simplify a

preventative or therapeutic approach [78]. Replication of our findings in other head and neck

cancer datasets and use of individual-level follow-up data with HPV status could provide

further insight into the effect of these genetic instruments on risk, treatment outcomes and

survival in head and neck cancer. With more evidence, future randomised control trials could

focus on treating high risk OC or OPC groups, such as those with severe dysplasia or who are

HPV-16 E6 positive, with cholesterol-lowering therapies.

Data availability statement

Summary-level analysis was conducted using publicly available GWAS data [25, 33]. Full summary statistics for the GAME-ON GWAS can be accessed via dbGAP (OncoArray: Oral and Pharynx Cancer; study accession number: phs001202.v1.p1) [34]. Access to UK Biobank (https://www.ukbiobank.ac.uk/) data is available to researchers through application.

Code availability statement

Two-sample MR analyses were conducted using the "TwoSampleMR" package in R (version 3.5.3). A copy of the code used in this analysis will be made available at: https://github.com/rcrichmond/cholesterol_lowering_headandneckcancer

Acknowledgements

M.G. was a National Institute for Health Research (NIHR) academic clinical fellow and is currently supported by a Wellcome Trust GW4-Clinical Academic Training PhD Fellowship. This research was funded in part, by the Wellcome Trust [Grant number 220530/Z/20/Z]. For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. UK Biobank approval was given for this project (ID 40644 "Investigating aetiology, associations and causality in diseases of the head and neck") and UK Biobank GWAS data was also accessed under the application (ID 15825 "MR-Base: an online resource for Mendelian randomization using summary data"-

Dr Philip Haycock). R.C.R. is a de Pass VC research fellow at the University of Bristol. J.T. is

supported by an Academy of Medical Sciences (AMS) Springboard award, which is supported

by the AMS, the Wellcome Trust, Global Challenges Research Fund (GCRF), the Government

Department of Business, Energy and Industrial strategy, the British Heart Foundation and

Diabetes UK (SBF004\1079). R.M.M. was supported by a Cancer Research UK

(C18281/A19169) programme grant (the Integrative Cancer Epidemiology Programme) and is

part of the Medical Research Council Integrative Epidemiology Unit at the University of Bristol

supported by the Medical Research Council (MC_UU_12013/1, MC_UU_12013/2, and

MC_UU_12013/3) and the University of Bristol. JY is supported by a Cancer Research UK

Population Research Postdoctoral Fellowship (C68933/A28534). R.M.M. and A.R.N. are

supported by the National Institute for Health Research (NIHR) Bristol Biomedical Research

Centre which is funded by the National Institute for Health Research (NIHR) and is a

partnership between University Hospitals Bristol and Weston NHS Foundation Trust and the

University of Bristol. This publication presents data from the Head and Neck 5000 study. The

study was a component of independent research funded by the NIHR under its Programme

Grants for Applied Research scheme (RP-PG-0707-10034). The views expressed in this

publication are those of the author(s) and not necessarily those of the NHS, the NIHR or the

Department of Health. Core funding was also provided through awards from Above and

Beyond, University Hospitals Bristol Research Capability Funding and the NIHR Senior

Investigator award to A.R.N. Human papillomavirus (HPV) serology was supported by a Cancer

Research UK Programme Grant, the Integrative Cancer Epidemiology Programme (grant

number: C18281/A19169). B.D. and the University of Pittsburgh head and neck cancer case-

control study are supported by US National Institutes of Health (NIH) grants: P50 CA097190,

P30 CA047904 and R01 DE025712. The genotyping of the HNSCC cases and controls was

performed at the Center for Inherited Disease Research (CIDR) and funded by the US National

Institute of Dental and Craniofacial Research (NIDCR; 1X01HG007780-0). The University of

North Caroline (UNC) CHANCE study was supported in part by the National Cancer Institute

(R01-CA90731). E.E.V and D.L are supported by Diabetes UK (17/0005587). E.E.V is also

supported by the World Cancer Research Fund (WCRF UK), as part of the World Cancer

Research Fund International grant programme (IIG_2019_2009). E.H.T and P.S. were

supported by the GENCAPO/FAPESP grant (10/51168-0).

Competing Interests

The authors declare no conflicts of interest. The funders had no role in the design of

the study; the collection, analysis, and interpretation of the data; the writing of the

manuscript; and the decision to submit the manuscript for publication. The authors alone are

responsible for the views expressed in this article.

References

1.   Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral

Oncol. 2009;45(4-5):309-16.

2.   Saba NF, Goodman M, Ward K, Flowers C, Ramalingam S, Owonikoko T, et al. Gender

and ethnic disparities in incidence and survival of squamous cell carcinoma of the oral

tongue, base of tongue, and tonsils: a surveillance, epidemiology and end results program-

based analysis. Oncology. 2011;81(1):12-20.

3.   Cancer Research UK (CRUK). Head and neck cancer statistics 2019 [cited 2019

11/04/2019]. Available from: https://www.cancerresearchuk.org/health-

professional/cancer-statistics/statistics-by-cancer-type/head-and-neck-cancers#heading-

Two.

4.   Mehanna H, Kong A, Ahmed SK. Recurrent head and neck cancer: United Kingdom

National Multidisciplinary Guidelines. J Laryngol Otol. 2016;130(S2):S181-S90.

5.   De Boer MF, McCormick LK, Pruyn JF, Ryckman RM, van den Borne BW. Physical and

psychosocial correlates of head and neck cancer: a review of the literature. Otolaryngol

Head Neck Surg. 1999;120(3):427-36.

6.   Thomas SJ, Penfold CM, Waylen A, Ness AR. The changing aetiology of head and neck

squamous cell cancer: A tale of three cancers? Clin Otolaryngol. 2018;43(4):999-1003.

7.   Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, et al. Human

papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med.

2010;363(1):24-35.

8.   Elrefaey S, Massaro MA, Chiocca S, Chiesa F, Ansarin M. HPV in oropharyngeal

cancer: the basics to know in clinical practice. Acta Otorhinolaryngol Ital. 2014;34(5):299-

309.

9.   Sleire L, Forde HE, Netland IA, Leiss L, Skeie BS, Enger PO. Drug repurposing in

cancer. Pharmacol Res. 2017;124:74-91.

10.   Hu M, Cheung BM, Tomlinson B. Safety of statins: an update. Ther Adv Drug Saf.

2012;3(3):133-44.

11.   Audi S, Burrage DR, Lonsdale DO, Pontefract S, Coleman JJ, Hitchings AW, et al. The

'top 100' drugs and classes in England: an updated 'starter formulary' for trainee

prescribers. British Journal of Clinical Pharmacology. 2018;84(11):2562-71.

12.   Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA

reductase. Science. 2001;292(5519):1160-4.

13.   Ference BA, Kastelein JJP, Ginsberg HN, Chapman MJ, Nicholls SJ, Ray KK, et al.

Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein

Levels and Cardiovascular Risk. JAMA. 2017;318(10):947-56.

14.   Nielsen SF, Nordestgaard BG, Bojesen SE. Statin Use and Reduced Cancer-Related

Mortality. New Engl J Med. 2012;367(19):1792-802.

15.   Mehibel M, Ortiz-Martinez F, Voelxen N, Boyers A, Chadwick A, Telfer BA, et al.

Statin-induced metabolic reprogramming in head and neck cancer: a biomarker for targeting

monocarboxylate transporters. Sci Rep. 2018;8(1):16804.

16.   Chawda JG, Jain SS, Patel HR, Chaduvula N, Patel K. The relationship between serum

lipid levels and the risk of oral cancer. Indian J Med Paediatr Oncol. 2011;32(1):34-7.

17.   Mehta R, Gurudath S, Dayansoor S, Pai A, Ganapathy KS. Serum lipid profile in

patients with oral cancer and oral precancerous conditions. Dent Res J (Isfahan).

2014;11(3):345-50.

18.   Kao LT, Hung SH, Kao PF, Liu JC, Lin HC. Inverse association between statin use and

head and neck cancer: Population-based case-control study in Han population. Head Neck-J

Sci Spec. 2019;41(5):1193-8.

19.   Dickerman BA, Garcia-Albeniz X, Logan RW, Denaxas S, Hernan MA. Avoidable flaws

in observational analyses: an application to statins and cancer. Nat Med. 2019;25(10):1601-

6.

20.   Smith GD, Ebrahim S. 'Mendelian randomization': can genetic epidemiology

contribute to understanding environmental determinants of disease? Int J Epidemiol.

2003;32(1):1-22.

21.   Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal

inference in epidemiological studies. Hum Mol Genet. 2014;23(R1):R89-98.

22.   Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation studies: a

guide, glossary, and checklist for clinicians. BMJ. 2018;362:k601.

23.   Walker VM, Smith GD, Davies NM, Martin RM. Mendelian randomization: a novel

approach for the prediction of adverse drug events and drug repurposing opportunities. Int J

Epidemiol. 2017;46(6):2078-89.

24.   Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M, et al.

Biological, clinical and population relevance of 95 loci for blood lipids. Nature.

2010;466(7307):707-13.

25.   Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni S, et al.

Discovery and refinement of loci associated with lipid levels. Nat Genet. 2013;45(11):1274-+.

26.   Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-

density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic,

epidemiologic, and clinical studies. A consensus statement from the European

Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459-72.

27.   Ference BA, Majeed F, Penumetcha R, Flack JM, Brook RD. Effect of naturally random

allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease

mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 x 2 factorial Mendelian

randomization study. J Am Coll Cardiol. 2015;65(15):1552-61.

28.   Ference BA, Robinson JG, Brook RD, Catapano AL, Chapman MJ, Neff DR, et al.

Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes. N Engl J

Med. 2016;375(22):2144-53.

29.   Carter P, Vithayathil M, Kar S, Potluri R, Mason AM, Larsson SC, et al. Predicting the

effect of statins on cancer risk using genetic variants: a Mendelian randomization study in

UK Biobank. medRxiv. 2020:2020.02.28.20028902.

30.   Yarmolinsky J, Bull CJ, Vincent EE, Robinson J, Walther A, Smith GD, et al. Association

Between Genetically Proxied Inhibition of HMG-CoA Reductase and Epithelial Ovarian

Cancer. JAMA. 2020;323(7):646-55.

31.   Machiela MJ, Chanock SJ. LDlink: a web-based application for exploring population-

specific haplotype structure and linking correlated alleles of possible functional variants.

Bioinformatics. 2015;31(21):3555-7.

32.   Ference BA, Ray KK, Catapano AL, Ference TB, Burgess S, Neff DR, et al. Mendelian

Randomization Study of ACLY and Cardiovascular Disease. N Engl J Med. 2019;380(11):1033-

42.

33.   Kettunen J, Demirkan A, Wurtz P, Draisma HH, Haller T, Rawal R, et al. Genome-wide

study for circulating metabolites identifies 62 loci and reveals novel systemic effects of LPA.

Nat Commun. 2016;7:11122.

34.   Lesseur C, Diergaarde B, Olshan AF, Wunsch V, Ness AR, Liu G, et al. Genome-wide

association analyses identify new susceptibility loci for oral cavity and pharyngeal cancer.

Nat Genet. 2016;48(12):1544-50.

35.   Consortium O. Consortium launches genotyping effort. Cancer Discov.

2013;3(12):1321-2.

36.   Dudding T, Johansson M, Thomas SJ, Brennan P, Martin RM, Timpson NJ. Assessing

the causal association between 25-hydroxyvitamin D and the risk of oral and oropharyngeal

cancer using Mendelian randomization. Int J Cancer. 2018;143(5):1029-36.

37.   Brion MJ, Shakhbazov K, Visscher PM. Calculating statistical power in Mendelian

randomization studies. Int J Epidemiol. 2013;42(5):1497-501.

38.   Yavorska OO, Burgess S. MendelianRandomization: an R package for performing

Mendelian randomization analyses using summarized data. Int J Epidemiol.

2017;46(6):1734-9.

39.   Burgess S, Scott RA, Timpson NJ, Davey Smith G, Thompson SG. Using published data

in Mendelian randomization: a blueprint for efficient identification of causal risk factors. Eur

J Epidemiol. 2015;30(7):543-52.

40.   Burgess S, Dudbridge F, Thompson SG. Combining information on multiple

instrumental variables in Mendelian randomization: comparison of allele score and

summarized data methods. Stat Med. 2016;35(11):1880-906.

41.   Nikpay M, Goel A, Won HH, Hall LM, Willenborg C, Kanoni S, et al. A comprehensive

1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease.

Nat Genet. 2015;47(10):1121-30.

42.   Hemani G, Bowden J, Smith GD. Evaluating the potential role of pleiotropy in

Mendelian randomization studies. Hum Mol Genet. 2018;27(R2):R195-R208.

43.   Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid

instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol.

2015;44(2):512-25.

44.   Bowden J, Smith GD, Haycock PC, Burgess S. Consistent Estimation in Mendelian

Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genet

Epidemiol. 2016;40(4):304-14.

45.   Hartwig FP, Smith GD, Bowden J. Robust inference in summary data Mendelian

randomization via the zero modal pleiotropy assumption. Int J Epidemiol. 2017;46(6):1985-

98.

46.   Bowden J, Del Greco MF, Minelli C, Smith GD, Sheehan NA, Thompson JR. Assessing

the suitability of summary data for two-sample Mendelian randomization analyses using

MR-Egger regression: the role of the I-2 statistic. Int J Epidemiol. 2016;45(6):1961-74.

801 47. Bowden J, Spiller W, Del Greco F, Sheehan N, Thompson J, Minelli C, et al. Improving

802 the visualization, interpretation and analysis of two-sample summary data Mendelian

803 randomization via the Radial plot and Radial regression. Int J Epidemiol. 2018;47(4):1264-78.

804 48. Verbanck M, Chen CY, Neale B, Do R. Publisher Correction: Detection of widespread

805 horizontal pleiotropy in causal relationships inferred from Mendelian randomization

806 between complex traits and diseases. Nat Genet. 2018;50(8):1196.

807 49. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. Genome-wide

808 genetic data on ~500,000 UK Biobank participants. bioRxiv. 2017:166298.

809 50. Mitchell R, Hemani, G, Dudding, T, Corbin, L, Harrison, S, Paternoster, L. UK Biobank

810 Genetic Data: MRC-IEU Quality Control, version 2.

811 https://doi.org/10.5523/bris.1ovaau5sxunp2cv8rcy88688v. 2019.

812 51. Mitchell R, Elsworth BL, Raistrick CA, Paternoster L, Hemani G, Gaunt TR MRC IEU UK

813 Biobank GWAS pipeline version 2. https://doi.org/10.5523/bris.pnoat8cxo0u52p6ynfaekeigi.

814 2019.

815 52. Schwarzer G. meta: an R package for metaanalysis. R News. 2007;7:40-5.

816 53. Higgins SG. Measuring inconsistency in metaanalyses. BMJ Br Med J. 2003;327:557-

817 60.

818 54. Safarova MS, Satterfield BA, Fan X, Austin EE, Ye Z, Bastarache L, et al. A phenome-

819 wide association study to discover pleiotropic effects of PCSK9, APOB, and LDLR. NPJ Genom

820 Med. 2019;4:3.

55.   Stoekenbroek RM, Lambert G, Cariou B, Hovingh GK. Inhibiting PCSK9 - biology

beyond LDL control. Nat Rev Endocrinol. 2018;15(1):52-62.

56.   Lee S, Zhang C, Liu Z, Klevstig M, Mukhopadhyay B, Bergentall M, et al. Network

analyses identify liver-specific targets for treating liver diseases. Mol Syst Biol.

2017;13(8):938.

57.   Marimuthu A, Subbannayya Y, Sahasrabuddhe NA, Balakrishnan L, Syed N, Sekhar

NR, et al. SILAC-based quantitative proteomic analysis of gastric cancer secretome.

Proteomics Clin Appl. 2013;7(5-6):355-66.

58.   Dong B, Singh AB, Fung C, Kan K, Liu J. CETP inhibitors downregulate hepatic LDL

receptor and PCSK9 expression in vitro and in vivo through a SREBP2 dependent

mechanism. Atherosclerosis. 2014;235(2):449-62.

59.   Barter PJ, Cochran BJ, Rye KA. CETP inhibition, statins and diabetes. Atherosclerosis.

2018;278:143-6.

60.   The Human Protein Atlas. PCKS9 2020 [Available from:

https://www.proteinatlas.org/ENSG00000169174-PCSK9/pathology.

61.   The Human Protein Atlas. LDLR 2020 [Available from:

https://www.proteinatlas.org/ENSG00000130164-LDLR/pathology.

62.   The Human Protein Atlas. LDLR Tissue 2020 [Available from:

https://www.proteinatlas.org/ENSG00000130164-LDLR/tissue.

63.   Lee JS, Mukhopadhyay P, Matyas C, Trojnar E, Paloczi J, Yang YR, et al. PCSK9

inhibition as a novel therapeutic target for alcoholic liver disease. Scientific Reports.

2019;9(1):17167.

64.   Lee JS, Rosoff D, Luo A, Longley M, Phillips M, Charlet K, et al. PCSK9 is Increased in

Cerebrospinal Fluid of Individuals With Alcohol Use Disorder. Alcoholism: Clinical and

Experimental Research. 2019;43(6):1163-9.

65.   Wang K, Gerke TA, Chen X, Prosperi M. Association of statin use with risk of Gleason

score-specific prostate cancer: A hospital-based cohort study. Cancer Medicine.

2019;8(17):7399-407.

66.   Poynter JN, Gruber SB, Higgins PD, Almog R, Bonner JD, Rennert HS, et al. Statins and

the risk of colorectal cancer. N Engl J Med. 2005;352(21):2184-92.

67.   Khurana V, Bejjanki HR, Caldito G, Owens MW. Statins reduce the risk of lung cancer

in humans: a large case-control study of US veterans. Chest. 2007;131(5):1282-8.

68.   Shannon J, Tewoderos S, Garzotto M, Beer TM, Derenick R, Palma A, et al. Statins

and prostate cancer risk: a case-control study. Am J Epidemiol. 2005;162(4):318-25.

69.   Cholesterol Treatment Trialists C, Emberson JR, Kearney PM, Blackwell L, Newman C,

Reith C, et al. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of

individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One.

2012;7(1):e29849.

70.   Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk: a

meta-analysis. JAMA. 2006;295(1):74-80.

71.   Hernan MA, Sauer BC, Hernandez-Diaz S, Platt R, Shrier I. Specifying a target trial

prevents immortal time bias and other self-inflicted injuries in observational analyses. J Clin

Epidemiol. 2016;79:70-5.

72.   Saka Herran C, Jane-Salas E, Estrugo Devesa A, Lopez-Lopez J. Protective effects of

metformin, statins and anti-inflammatory drugs on head and neck cancer: A systematic

review. Oral Oncol. 2018;85:68-81.

73.   Dimitroulakos J, Marhin WH, Tokunaga J, Irish J, Gullane P, Penn LZ, et al. Microarray

and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas.

Neoplasia. 2002;4(4):337-46.

74.   Osmak M. Statins and cancer: current and future prospects. Cancer Lett.

2012;324(1):1-12.

75.   Gallagher EJ, LeRoith D. Obesity and Diabetes: The Increased Risk of Cancer and

Cancer-Related Mortality. Physiol Rev. 2015;95(3):727-48.

76.   Joost HG. Diabetes and cancer: Epidemiology and potential mechanisms. Diabetes

Vasc Dis Re. 2014;11(6):390-4.

77.   Hursting SD, DiGiovanni J, Dannenberg AJ, Azrad M, LeRoith D, Demark-Wahnefried

W, et al. Obesity, Energy Balance, and Cancer: New Opportunities for Prevention. Cancer

Prev Res. 2012;5(11):1260-72.

78.   Bhat M, Skill N, Marcus V, Deschenes M, Tan X, Bouteaud J, et al. Decreased PCSK9

expression in human hepatocellular carcinoma. BMC Gastroenterol. 2015;15:176.

Fig 1. Forest plot showing the causal effects of *HMGCR*, *NPC1L1, CETP, PCSK9* and *LDLR*

variants on the oral and oropharyngeal cancer subsites in GAME-ON.

901 Effect estimates on oral and oropharyngeal cancer are reported on the log odds scale.

Effect estimates on oral and oropharyngeal cancer are reported on the log odds scale.

Fig 2. Forest plots showing the causal effects of cholesterol-lowering *PCSK9* and *LDLR* single nucleotide polymorphisms on coronary heart disease and combined oral/ oropharyngeal cancer in GAME-ON.

Effect estimates on oral and oropharyngeal cancer are reported on the log odds scale.

Fig 3. Scatter plots for *LDLR* and PCSK9 single nucleotide polymorphisms effect on combined oral/ oropharyngeal cancer in GAME-ON.

Fig 4. Forest plots showing inverse variance weighted meta-analysis effects of cholesterol-lowering *PCSK9* single nucleotide polymorphisms on head and neck cancer subsites .

Fig 5. Forest plots showing inverse variance weighted meta-analysis effects of cholesterol-lowering

LDLR single nucleotide polymorphisms on head and neck cancer subsites